Literature DB >> 16464536

Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin.

D Mukherjea1, C A Whitworth, S Nandish, G A Dunaway, L P Rybak, V Ramkumar.   

Abstract

Cisplatin is a widely used chemotherapeutic agent whose dose-limiting side effects include ototoxicity and nephrotoxicity. Recent evidence indicates that cisplatin induces the expression of a novel protein, kidney injury molecule-1, in the renal proximal tubular epithelium to aid in regeneration. In this study, we determined whether kidney injury molecule-1 is expressed in the cochlea and is induced by cisplatin. Using reverse transcriptase polymerase chain reaction techniques, we have now identified kidney injury molecule-1 in the rat cochlea and in three different mouse transformed hair cell lines. Administration of cisplatin to rats produced hearing loss and induced kidney injury molecule-1 mRNA in the rat cochlea. Pretreatment of rats with lipoic acid, a scavenger of reactive oxygen species, significantly reduced cisplatin-induced hearing loss and kidney injury molecule-1 expression. Cisplatin also increased the expression of cochlear NOX3 mRNA, a member of the superoxide generating NADPH oxidase family of proteins recently identified in the cochlea, inhibition of which decreased kidney injury molecule-1 expression. Polymerase chain reaction performed on different regions of the cochlea indicated the presence of kidney injury molecule-1 mRNA in the lateral wall, organ of Corti and spiral ganglion. This distribution was confirmed by immunocytochemistry. Taken together, these data identify kidney injury molecule-1 as a novel cochlear injury molecule, whose expression is regulated by reactive oxygen species generated via the NADPH oxidase pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464536     DOI: 10.1016/j.neuroscience.2005.12.044

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  29 in total

1.  Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Tejbeer Kaur; Kelly E Sheehan; Vickram Ramkumar; Leonard P Rybak
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

Review 2.  Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.

Authors:  Corné J Kros; Peter S Steyger
Journal:  Cold Spring Harb Perspect Med       Date:  2019-11-01       Impact factor: 6.915

Review 3.  An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Toxicol Lett       Date:  2015-06-20       Impact factor: 4.372

Review 4.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement.

Authors:  Sebastian Altenhöfer; Kim A Radermacher; Pamela W M Kleikers; Kirstin Wingler; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2014-02-26       Impact factor: 8.401

5.  Development and validation of a cisplatin dose-ototoxicity model.

Authors:  Marilyn F Dille; Debra Wilmington; Garnett P McMillan; Wendy Helt; Stephen A Fausti; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2012 Jul-Aug       Impact factor: 1.664

6.  Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Craig Whitworth; Jennifer R Bunch; Jeremy G Turner; Leonard P Rybak; Vickram Ramkumar
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

Review 7.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

8.  Proteomic analysis of the balance between survival and cell death responses in cisplatin-mediated ototoxicity.

Authors:  Samson Jamesdaniel; Dalian Ding; Mohammad Habiby Kermany; Bruce A Davidson; Paul R Knight; Richard Salvi; Donald E Coling
Journal:  J Proteome Res       Date:  2008-06-26       Impact factor: 4.466

Review 9.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

10.  Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity.

Authors:  Kelly Sheehan; Sandeep Sheth; Debashree Mukherjea; Leonard P Rybak; Vickram Ramkumar
Journal:  J Vis Exp       Date:  2018-03-16       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.